OncLive TV

Andrew D. Seidman, MD, from the Memorial Sloan-Kettering Cancer Center, describes his excitement over the genetic advances made in the treatment of patients with cancer.

Ann H. Partridge, MD, MPH, from Dana-Farber Cancer Institute and Harvard Medical School, gives an overview of the Adult Survivorship Program.

Richard L. Schilsky, MD, from the University of Chicago Comprehensive Cancer Center, discusses sequestration and the effect on the FDA.

James L. Gulley, MD, PhD, Head, Clinical Trials Group, Deputy Laboratory Chief, National Cancer Institute (NCI), gives an overview of the adverse event profile for PROSTVAC.

Julian Adams, PhD, from Infinity Pharmaceuticals, describes the mechanism of action for the experimental PI3 kinase delta/gamma inhibitor IPI-145 in hematologic malignancies.

Craig L. Tendler, MD, Vice President, Late Development and Global Medical Affairs for Oncology, Janssen Oncology, discusses the importance of ibrutinib's Breakthrough Therapy Designation.

Edith Mitchell, MD, FACP, from Thomas Jefferson University, gives an overview of the North American subgroup analysis of the VELOUR trial.

G. Thomas Budd, MD, Medical Oncologist, Taussig Cancer Center at Cleveland Clinic, discusses the background and results of the S0221 trial in breast cancer.

Ellen T. Matloff, MS, CGC, from the Yale School of Medicine/Yale Cancer Center, describes the impact of the US Supreme Court decision to restrict the patenting of segments of DNA in isolation.

David D. Chang, MD, PhD, head of global oncology development at Amgen, discusses the design of the TRINOVA-1 trial in ovarian cancer.

Jane Robertson, MD, Global Product Vice President for olaparib at AstraZeneca, discusses a trial looking at olaparib for patients with serous ovarian cancer.

Jeffrey S. Weber, MD, PhD, from the Moffitt Cancer Center and Research Institute, describes a single institution phase I/II trial exploring the anti-PD-1 antibody nivolumab in combination with a peptide vaccine for patients with unresectable melanoma.

Catherine Bollard, MBChB, MD, Professor of Pediatrics, Medicine, and Pathology & Immunology, Baylor College of Medicine, discusses the treatment of EBV-positive lymphoma with T-cell therapy.

Clifford A. Hudis, MD, chief of the Breast Cancer Medicine Service at Memorial Sloan-Kettering Cancer Center in New York, discusses the findings of the CALGB 40601 study in breast cancer.

Neal D. Shore, MD, FACS, Medical Director, Carolina Urologic Research Center, Myrtle Beach, gives an overview of the development of immunotherapies for patients with prostate cancer.

Jedd D. Wolchok, MD, PhD, from the Memorial Sloan-Kettering Cancer Center, discusses a phase I trial exploring the combination of the anti-PD-1 antibody nivolumab and ipilimumab, a CTLA-4 inhibitor, for patients with advanced melanoma.

Valentin Goede, MD, Department I of Internal Medicine and Center of Integrated Oncology Cologne-Bonn, University of Cologne, Germany, discusses the findings of the phase III CLL11 trial.

Daniel J. George, MD, from the Duke Cancer Institute, elaborates on the incorporation of radium-223 into the treatment of patients with metastatic castration-resistant prostate cancer.

Daniel H. Fowler, MD, senior investigator, Center for Cancer Research, National Cancer Institute, describes the mechanism of action of T-rapa cells.

Jeffrey D. Bradley, MD, Professor, Radiation Oncology, Washington University School of Medicine in St. Louis, discusses the background of the phase III RTOG 0617 study.

Dawn L. Hershman, MD, MS, discusses improving care and the use of compendia-approved oncology drugs.

Glenn J. Lesser, MD, discusses the background of the RTOG 0424 study, which analyzed temozolomide in high-risk low-grade gliomas.

Joyce A. O'Shaughnessy, MD, from the Baylor Charles A. Sammons Cancer Center, reviews findings from Study 301, which compared eribulin mesylate to capecitabine for patients with locally advanced or metastatic breast cancer.

Rebecca L. Aft, MD, PhD, discusses the identification of patients with breast cancer at high risk of recurrent disease development by detection of HER2-positive disseminated tumor cells in bone marrow of patients with HER2-negative tumors.

D. Ross Camidge, MD, PhD, Director, Thoracic Oncology Clinical Program, University of Colorado Cancer Center, discusses the use of crizotinib as a ROS1 inhibitor in non-small cell lung cancer (NSCLC).

Thomas Hutson, DO, PharmD, discusses tivozanib for the treatment of advanced renal cell carcinoma (RCC).

Yvonne M. Saenger, MD, Assistant Professor in Medicine and Dermatology, Hematology and Medical Oncology, Mount Sinai School of Medicine, discusses the idea of combining targeted and immune agents.

Robert Figlin, MD, FACP, discusses the sequencing of mTOR inhibitors and tyrosine kinase inhibitors in renal cell carcinoma.

Bayard L. Powell, MD, from the Wake Forest Baptist Medical Center Comprehensive Cancer Center, discusses a phase I study that explored the first-in-class mitochondrial metabolism inhibitor CPI-613 in patients with advanced hematologic malignancies.

Brian A. Van Tine, MD, PhD, Assistant Professor, Washington University School of Medicine in St. Louis, discusses the use of arginine deiminase (ADI-PEG20) for the treatment of sarcomas.